ArticleJournal of applied genetics2026
Investigation of testicular METRNL and RARRES2 expression in non-obstructive azoospermia.
Article in Journal of applied genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Non-obstructive azoospermia is a severe form of male infertility characterized by impaired spermatogenesis. Given the strong evidence linking obesity and chronic inflammation to male reproductive dysfunction, we aimed to investigate the role of adipokines METRNL (Meteorin-like protein) and RARRES2 (Chemerin) in non-obstructive azoospermia pathogenesis. We conducted a retrospective study using the testicular biopsy samples of 35 patients (12 cases were obese, 23 cases had normal body mass index) with non-obstructive azoospermia and 18 patients with obstructive azoospermia and/or vas deferens agenesis. We compared the testicular METRNL and RARRES2 mRNA expressions of obese and non-obese non-obstructive azoospermia cases with controls (obstructive azoospermia cases with intact spermatogenesis). We detected significantly increased RARRES2 expression in both obese and non-obese non-obstructive azoospermia patients. Even though statistically non-significant, we observed a higher RARRES2 expression trend in histologically more severe non-obstructive azoospermia cases. We also detected a significant inverse correlation between RARRES2 expression and Johnsen score, an indicator of seminiferous tubule integrity and spermatogenesis status. Conversely, we found no significant difference in METRNL expression across the study groups. Broader studies are needed to validate our results and investigate the mechanisms of increased RARRES2 (chemerin) expression in the azoospermia cases with defective spermatogenesis.
Indexed as
Identifiers
42581226What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.